Literature DB >> 18672473

MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD.

R S Desikan1, B Fischl, H J Cabral, T L Kemper, C R G Guttmann, D Blacker, B T Hyman, M S Albert, R J Killiany.   

Abstract

BACKGROUND: MRI studies have demonstrated differential rates of atrophy in the entorhinal cortex and hippocampus during the prodromal phase of Alzheimer disease (AD). The current study was designed to determine whether a broader set of temporoparietal regions show differential rates of atrophy during the evolution of AD.
METHODS: Sixteen regions of interest (ROIs) were analyzed on MRI scans obtained at baseline and follow-up in 66 subjects comprising three groups: controls = individuals who were cognitively normal at both baseline and follow-up; nonconverters = subjects with mild cognitive impairment (MCI) at both baseline and follow-up; converters had MCI at baseline but had progressed to AD at follow-up.
RESULTS: Annualized percent change was analyzed with multivariate analysis of variance (MANOVA), covaried for age. The MANOVA demonstrated an effect of group (p = 0.004). Post hoc comparisons demonstrated greater rates of atrophy for converters vs nonconverters for six ROIs: hippocampus, entorhinal cortex, temporal pole, middle temporal gyrus, fusiform gyrus, and inferior temporal gyrus. Converters showed differentially greater rates of atrophy than controls in five of the same ROIs (and inferior parietal lobule). Rates of change in clinical status were correlated with the atrophy rates in these regions. Comparisons between controls and nonconverters demonstrated no differences.
CONCLUSION: These results demonstrate that temporoparietal regions show differential rates of atrophy on MRI during prodromal Alzheimer disease (AD). MRI data correlate with measures of clinical severity and cognitive decline, suggesting the potential of these regions of interest as antemortem markers of prodromal AD.

Entities:  

Mesh:

Year:  2008        PMID: 18672473      PMCID: PMC2577003          DOI: 10.1212/01.wnl.0000320055.57329.34

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  MRI measures of entorhinal cortex vs hippocampus in preclinical AD.

Authors:  R J Killiany; B T Hyman; T Gomez-Isla; M B Moss; R Kikinis; F Jolesz; R Tanzi; K Jones; M S Albert
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

2.  Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images.

Authors:  N C Fox; W R Crum; R I Scahill; J M Stevens; J C Janssen; M N Rossor
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

3.  Imaging the progression of Alzheimer pathology through the brain.

Authors:  A David Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

4.  Comparison of methods for measuring longitudinal brain change in cognitive impairment and dementia.

Authors:  V A Cardenas; A T Du; D Hardin; F Ezekiel; P Weber; W J Jagust; H C Chui; N Schuff; M W Weiner
Journal:  Neurobiol Aging       Date:  2003 Jul-Aug       Impact factor: 4.673

5.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease.

Authors:  G M McKhann; M S Albert; M Grossman; B Miller; D Dickson; J Q Trojanowski
Journal:  Arch Neurol       Date:  2001-11

6.  Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.

Authors:  R J Killiany; T Gomez-Isla; M Moss; R Kikinis; T Sandor; F Jolesz; R Tanzi; K Jones; B T Hyman; M S Albert
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

7.  MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment.

Authors:  J L Whitwell; M M Shiung; S A Przybelski; S D Weigand; D S Knopman; B F Boeve; R C Petersen; C R Jack
Journal:  Neurology       Date:  2007-09-26       Impact factor: 9.910

8.  Higher atrophy rate of entorhinal cortex than hippocampus in AD.

Authors:  A T Du; N Schuff; J H Kramer; S Ganzer; X P Zhu; W J Jagust; B L Miller; B R Reed; D Mungas; K Yaffe; H C Chui; M W Weiner
Journal:  Neurology       Date:  2004-02-10       Impact factor: 9.910

9.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.

Authors:  C R Jack; M M Shiung; J L Gunter; P C O'Brien; S D Weigand; D S Knopman; B F Boeve; R J Ivnik; G E Smith; R H Cha; E G Tangalos; R C Petersen
Journal:  Neurology       Date:  2004-02-24       Impact factor: 9.910

10.  Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI.

Authors:  Rachael I Scahill; Jonathan M Schott; John M Stevens; Martin N Rossor; Nick C Fox
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

View more
  39 in total

Review 1.  Alliance for aging research AD biomarkers work group: structural MRI.

Authors:  Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Surgery and brain atrophy in cognitively normal elderly subjects and subjects diagnosed with mild cognitive impairment.

Authors:  Richard P Kline; Elizabeth Pirraglia; Hao Cheng; Susan De Santi; Yi Li; Michael Haile; Mony J de Leon; Alex Bekker
Journal:  Anesthesiology       Date:  2012-03       Impact factor: 7.892

3.  Minimal atrophy of the entorhinal cortex and hippocampus: progression of cognitive impairment.

Authors:  Daniel Varon; David A Loewenstein; Elizabeth Potter; Maria T Greig; Joscelyn Agron; Qian Shen; Weizhao Zhao; Maria Celeste Ramirez; Isael Santos; Warren Barker; Huntington Potter; Ranjan Duara
Journal:  Dement Geriatr Cogn Disord       Date:  2011-04-13       Impact factor: 2.959

4.  Structural imaging markers for therapeutic trials in Alzheimer's disease.

Authors:  N C Fox; J Kennedy
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 5.  Medial temporal cortices in ex vivo magnetic resonance imaging.

Authors:  Jean C Augustinack; André J W van der Kouwe; Bruce Fischl
Journal:  J Comp Neurol       Date:  2013-12-15       Impact factor: 3.215

Review 6.  Progression of atrophy in Alzheimer's disease and related disorders.

Authors:  Jennifer L Whitwell
Journal:  Neurotox Res       Date:  2010-03-30       Impact factor: 3.911

7.  Association of ApoE and LRP mRNA levels with dementia and AD neuropathology.

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Neurobiol Aging       Date:  2011-06-15       Impact factor: 4.673

8.  Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI.

Authors:  Martha Skup; Hongtu Zhu; Yaping Wang; Kelly S Giovanello; Ja-an Lin; Dinggang Shen; Feng Shi; Wei Gao; Weili Lin; Yong Fan; Heping Zhang
Journal:  Neuroimage       Date:  2011-02-26       Impact factor: 6.556

9.  Glucose Dysregulation Interacts With APOE-∊4 to Potentiate Temporoparietal Cortical Thinning.

Authors:  Jessica M Foley; David H Salat; Nikki H Stricker; Regina E McGlinchey; William P Milberg; Laura J Grande; Elizabeth C Leritz
Journal:  Am J Alzheimers Dis Other Demen       Date:  2015-05-24       Impact factor: 2.035

10.  Selective disruption of the cerebral neocortex in Alzheimer's disease.

Authors:  Rahul S Desikan; Mert R Sabuncu; Nicholas J Schmansky; Martin Reuter; Howard J Cabral; Christopher P Hess; Michael W Weiner; Alessandro Biffi; Christopher D Anderson; Jonathan Rosand; David H Salat; Thomas L Kemper; Anders M Dale; Reisa A Sperling; Bruce Fischl
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.